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CD4+ CD25+ regulatory T cells have been shown to maintain peripheral tolerance 
against self and foreign antigens. In this study we analyse the effect of circulating 
CD4+ CD25+ T cells on CD8+ T cell response of patients with chronic and resolved 
HBV infection. We demonstrated that circulating CD4+ CD25+ T cells modulate the 
function and expansion of HBV-specific CD8+ cells ex vivo in all patients, regardless 
of whether they have chronic or resolved HBV infection. The possible role of 
CD4+CD25+ T cells in the pathogenesis of chronic HBV infection is not supported 
by these data. However, these results might have implications for optimising future 
immunotherapeutic approaches to HBV treatment. 
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Introduction 
HBV is a non-cytopathic, hepatotropic DNA virus that infects more than 300 million 
people world–wide, causing liver disease of variable severity (15). The pathogenesis 
of the liver damage during HBV infection is immune-mediated, and is dependent on 
the balance between viral replication and the CD8+ T cell response (7). Virus-specific 
CD8+ cells are necessary for HBV control (25) but are defective in patients with 
persistent HBV infection when compared with those who resolved infection(11). High 
antigen dose deletion(28) and lack of CD4 help (13) could explain the low number of 
virus-specific CD8+ cells present in patients with chronic infection. However, it 
remains possible that other direct mechanisms of regulation of CD8+ expansion 
operate in patients with chronic HBV infection, that still possess low frequencies of 
virus specific CD8+ cells in lymph nodes(18), liver(17) and blood(28). The 
suggestion that a residual population of cells is actively suppressed in chronic HBV 
infection is supported by the boosting of their frequencies on reduction of viral load 
with antiviral therapy(9).   
 
Studies in a large number of experimental models have provided convincing evidence 
that a population of specialised T cells able to actively regulate the immune response 
represents an integral part of the T cell repertoire (19, 21). These cells have been 
shown to suppress immunological responses against self (3, 22) and foreign antigens 
(1, 6, 12, 24) and reside mainly, but not exclusively, within a minor subpopulation of 
CD4+ cells that express the phenotypic marker CD25 (4). The mechanisms that 
mediate the regulatory effect of CD4+ CD25+ cells are still controversial, with 
evidence supporting regulation either through suppressive cytokines or direct cell-cell   4
contact (19). CD4+ CD25+ regulatory cells develop in the thymus and are anergic to 
antigenic stimulation in vitro, but recent experiments have demonstrated their ability 
to expand in vivo following Ag recognition(27). This ability of CD4+ CD25+ to 
respond to peripheral antigens could be particularly important in the regulation of 
immunopathological and protective responses to parasites (6)and viruses (1, 6, 12, 
24). In mice infected with HSV, CD4+ CD25+ cells were not only shown to regulate 
the clonal expansion of virus-specific CD8+ cells, but their suppressive function was 
also enhanced by the virus infection (24). These data suggest that during viral 
infection, CD4+ CD25+ cells can be modulated in the periphery after recognition of 
viral antigens. Furthermore, recent data in HCV-infected subjects has shown the 
potential ability of CD4+ CD25+ to regulate HCV-specific T cells in patients with 
chronic hepatitis C(23). These data raise the possibility that a dynamic regulation of 
virus-specific CD8+ responses can be mediated by CD4+ CD25+ during viral 
infection. 
 
It is possible that CD4+ CD25+ cells are activated in vivo to suppress the expansion 
of the HBV-specific CD8+ cells able to escape deletion, thus precluding HBV 
clearance, but limiting excessive immune-mediated liver damage. To test this 
possibility, we explored the impact of circulating CD4+ CD25+ regulatory T cells in 
patients with chronic and resolved hepatitis B. We investigated whether in vivo 
frequencies of CD4+ CD25+ cells differ according to the clinical outcome of HBV 
infection or correlate with the fluctuation of disease activity present during chronic 
infection. The direct influence of CD4+ CD25+ cells on the expansion and function of 
HBV-specific CD8+ cells from patients with chronic and resolved infection was then 
examined in vitro.    5
  
Material and methods 
 
Patients 
Blood was collected with informed consent from 40 patients infected with HBV. The 
study was approved by the local ethics committee. Three subjects (R1, R2, R3) had 
clinical, biochemical and virological evidence of resolved acute hepatitis B infection 
(recovered from acute hepatitis B: normal ALT levels, anti-HBc+, HBsAg negative). 
The remaining 37 patients had clinical, biochemical and virological evidence of 
chronic HBV infection. They were HBsAg and anti-HBc positive and negative for 
antibodies to hepatitis C virus (HCV), delta virus and to HIV-1, 2. Patients were not 
treated with antiviral therapy in the preceding 6 months, and had no other possible 
aetiologies for chronic liver diseases, such as alcohol, drugs, congestive cardiac 
failure or autoimmune disease. Frequency of CD4+ CD25+ cells was also tested in 
HBeAg+ patients who display drug-induced episodes of hepatic flares. These patients 
received, after the initial screening, 4 weeks of prednisolone treatment (30mg/day for 
2 weeks and 15mg/day for consecutive 2 weeks, followed by 2 weeks without 
treatment) and at week 6 they started Lamivudine (100mg/day). Hepatic flares occur 
when patients were on Lamivudine treatment only and 3-4 weeks after the 
discontinuation of prednisolone. The frequency of CD4+ CD25+ T cells was analysed 
before, during and after episodes of hepatic flares, when patients were on Lamivudine 
treatment. Blood from healthy donors who were negative for any serological markers 
of past or present HBV infection was also collected.  
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PBMC from HBV infected patients and healthy donors were isolated from 
heparinized whole blood by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) 
density gradient centrifugation. Cells were washed twice with RPMI 1640 (Autogen 
Bioclear UK Ltd, Calne, UK) and suspended in RPMI 1640 + 5% AB serum for 
further analysis. Screening for HLA-A2 positivity was performed by staining PBMC 
of patients with fluorescent conjugated anti-HLA-A0201 antibody (Serotec Ltd, 
Oxford, UK).  
 
Virological Assessment. HBsAg, anti-HBs, total and IgM anti-HBc, HBeAg, anti-
HBe, anti-delta, anti-HCV, anti-HIV-1 and anti-HIV-2 were determined by 
commercial enzyme immunoassay kits (Abbot Laboratories, North Chicago, IL; 
Ortho Diagnostic System, Raritan, NJ; Sanofi Diagnostic Pasteur, Marnes-la 
Coquette, France). Serum HBV-DNA was quantified by using the Roche Amplicor 
Monitor assay (Roche Pharmaceuticals Ltd., Branchburg, NJ), with a DNA detection 
limit threshold of 400 copies/ml (0.0014 pg/ml). 
 
Synthetic peptides. Peptides corresponding to the sequence of HBV genotype D 
were purchased from Primm (Milano, Italy). Purity was above 90% using HPLC 
analysis. The AA sequence of the peptides used is: core 18-27= FLPSDFFPSV, env 
183-91= FLLTRILTI, env 348-57= GLSPTVWLSV, pol 455-63= GLSRYVARL. A 
melanoma peptide (Melan-A 26-35 = ELAGIGILTV) was used as a control.  
 
Phenotype of CD4+ CD25+ T cells. Fresh or frozen PBMC were washed once in 
phosphate–buffer saline (PBS) containing 1% FCS and stained with fluorescently 
labelled antibodies for CD4-fluorescin isothiocynate (FITC), CD25-phycoerythrin   7
(PE) or anti-IgG2 control antibody( BD Biociences PharMingen, San Diego, 
California) for 20min at 4C. The cells were then washed twice with PBS containing 
1% FCS, and immediately acquired on a flow cytometer FACScan 
TM (Beckton 
Dickinson) and analysed using Cell Quest software. Frequency of CD4+CD25+ cells 
was analysed in frozen PBMC with viability > 80% (by Trypan Blu  analysis). 
Experiments showed that within this viability range, the CD4+ CD25+ T cell 
frequency was identical in fresh or frozen samples.  
 
Depletion of CD4+ CD25+ cells. CD4+ CD25+ cells were isolated from PBMC 
using the CD4+ CD25+ Regulatory T cell isolation Kit (Myltenyi Biotec, Auburn, 
CA), with a Midi Macs 
TM Separator unit, according to the manufacturer instructions. 
The efficiency of CD4+ CD25+ T cell depletion was > 90%. Untreated PBMC or 
PBMC depleted of CD4+ CD25+ cells were then used for producing short term T cell 
lines. In selected experiments, the positively selected CD4+ CD25+ cells were added 
back to depleted PBMC.   
 
Expansion of CD8+ T cell lines.  Total PBMC or PBMC depleted of CD4+ CD25+ 
cells (2-3 x106/well) were stimulated in RPMI + 10% FCS with 1µM of various 
peptides in a U bottom 96 well plate. Recombinant IL-2 (R&D systems, Abingdon, 
UK) was added on day 4 of culture and frequency and function of CD8+ cells were 
analysed after 10-12 days of culture. In selected experiments CD4+ CD25+ cells were 
added back to CD4+ CD25+ depleted PBMC at a responder/ regulator ratio of 20:1.  
 
Intracellular Interferon (IFN)-γ production. Short-term T cell lines were 
stimulated in RPMI 1640 10% FCS, with the initial stimulatory peptides (1µM), for 6   8
hours at 37°C in the presence of 10 µg Brefeldin A (Sigma-Aldrich, Poole, Dorset). 
Cells were washed, stained with Cy-chrome conjugated anti-CD8 antibodies, then 
permeabilized and fixed using Cytofix/Cytoperm (Pharmingen, San Diego) according 
to the manufacturers instructions. FITC-conjugated anti-cytokine antibodies or 
isotype-matched controls were added (30min, 4
0C), washed twice and cells were then 
analysed by flow cytometry.  
 
Staining with HLA-tetrameric complexes. HLA-class I tetramers were purchased 
commercially (Proimmune, Oxford, UK). Tc18-27 is an HLA-A2 tetramer specific 
for HLA-A2 restricted core18-27 specific CD8 cells, T mel, is specific for HLA-A2 
restricted Mage-1-specific CD8+ cells.  The tetramers were used to stain short term 
lines produced from PBMC of the patients. T cell lines were incubated for 30 min at 
37°C with 1µg of phycoerythrin-labelled tetrameric complex in RPMI 1640, 10% 
FCS in round-bottom polystyrene tubes (Becton Dickinson, NJ). Cells were washed 
in PBS and then incubated at 4°C for 30 min with saturating concentrations of directly 
conjugated anti-CD8/Cy-chrome (PE-Cy5) monoclonal antibody (mAb) (Sigma 
Chemical Co., St. Louis, MO)After further washing, cells were analysed on 
FACSort (Becton Dickinson) using CELLQuest software immediately or after 
addition of 1% paraformaldehyde.    9
Results and Discussion 
 
CD4+ CD25+ cells in the circulation of HBeAg+ patients with chronic hepatitis B. 
We tested the hypothesis that the inability to control viral replication and the absence 
of immune-mediated liver damage present in HBeAg+ immunotolerant patients were 
attributable to high levels of regulatory cells. The proportion of CD4+ CD25+ cells 
was quantified cross-sectionaly in different categories of patients with chronic HBV 
infection. 15 ‘immunotolerant’ patients (HBeAg+, HBV-DNA>10
7, transaminase 
levels < 70 U/L), 11 patients with clinical evidence of chronic active hepatitis B 
(HBeAg+, HBV-DNA>10
7, transaminase levels > 70 U/L) and 11 patients with 
asymptomatic HBV infection (HBsAg+, HBV-DNA < 10
6, transaminase levels 
normal) were selected. The frequency of CD4+ CD25+ cells present in these three 
groups of patients with chronic hepatitis B and a group of 14 healthy controls (Figure 
1a) was calculated using the gate shown in Figure 1a, which only selected CD25 high 
cells (Intensity of fluorescence> 3x10). CD25 high cells, which exhibit regulatory cell 
function, have been shown to represent about 1-3% of the total CD4+ cell population 
(4), whereas CD25 low cells can represent up to 15% of CD4+ T cells in healthy 
subjects. There is variability in the frequency of CD4+ CD25 high T cells within the 
groups of patients and healthy controls (Figure 1b). However, the mean frequency 
was 2.4 ± 1.1 in ‘immunotolerant patients, 2.8 ± 1.7in patients with chronic active 
hepatitis and 1.9 ± 0.9 in the asymptomatic patients: no statistically significant 
differences were found between the patients groups and healthy controls (2.5 ± 1.1) 
(Mann-Whitney test: p<0.73, p<0.71, p<0.08 respectively).  
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We then explored whether there was any reduction in CD4+ CD25+ cells temporally 
associated with hepatic flares of chronic hepatitis B. “Flares” of chronic hepatitis are 
generally interpreted as an indicator of recovery of HBV-specific immunity, which 
occurs spontaneously or during antiviral treatment (15). Here we quantified the 
frequency of CD4+CD25+ cells before, during and after episodes of hepatic flares 
occurring in HBeAg+ immunotolerant patients who have been treated with 
prednisolone and Lamivudine (see Material and methods). These hepatic flares 
occurred when patients were on Lamivudine treatment only, 3-4 weeks after the 
discontinuation of prednisolone.  This is a highly specific treatment regime which is 
likely to influence the pathogenesis of hepatic flares. It does, however, allow us to 
predict the occurrence of hepatic flares and thus to study immunological events that 
occur before and during ALT elevation. Figure 1c shows the direct ex vivo frequency 
of CD4+ CD25+ T cells in 5 patients who displayed elevated ALT ( > 100 U/L and 
twice the initial baseline value). A minimal decrease of CD4+ CD25+ frequency at 
the time of ALT elevation was found in 3 of these patients (3/5). Only one (1/5) 
showed a decrease of more than 1% (from 2.6% to 1.4%).  
 
To investigate whether these decreases in circulating CD4+ CD25+ frequencies had 
any impact on HBV-specific CD8+ responsiveness, we analysed in parallel HBV-
specific CD8 and CD4+ CD25+ frequency in two HLA-A2+ patients (Table I) . Both 
of these patients exhibited ALT elevations and fluctuations in CD4+ CD25+ cell 
frequencies (Figure 2). The frequency of HBV-specific CD8+ T cells was quantified 
directly ex vivo and after in vitro stimulation. In line with our previous work, HBV-
specific CD8+ cells could only be quantified in HBeAg+ patients after a round of in 
vitro expansion and not directly ex vivo. Of the 11 common HLA-A2 restricted CD8   11
epitopes tested(28), only env 183-91 and env 348-57 elicited a CD8+ T cell response 
in patient 3 and env 335-43 elicited a response in patient 7. As shown in figure 2, the 
fluctuations of HBV-specific CD8+ responses found in these two patients did not 
unequivocally correlate with increased or decreased frequencies of CD4+ CD25+ 
cells. 
 
Thus, frequency of circulating CD4+ CD25+ T cells did not correlate with the 
clinical, virological or immunological parameters present in patients with chronic 
hepatitis B.  Larger groups of patients with different profiles of chronic hepatitis B 
will need to be analysed to confirm these exploratory data, which are similar to those 
found in HIV (1) and multiple sclerosis(5). In these two systems, despite identical 
direct ex vivo frequencies in healthy subjects and patients, CD4+ CD25+ cells showed 
differential immunoregulatory activity according to clinical outcome. We therefore 
tested whether circulating CD4+ CD25+ cells found in chronic hepatitis B patients are 
functionally capable of suppressing immune responses to HBV ex vivo. 
 
CD4+ CD25+ T cells regulate CD8+ T cell responses ex vivo. PBMC from chronic 
hepatitis B patients with or without the CD4+ CD25+ fraction were stimulated with 
selected peptides corresponding to known HLA-A2 restricted HBV epitopes. The 
frequency of HBV-specific CD8+ cells was calculated by intracellular IFN-gamma 
production after 10 days of in vitro expansion (Figure 3). 
 
It is noteworthy that the patients analysed were carefully selected from a larger group 
of HLA-A2+ patients in whom the profile of HBV-specific CD8+ T cell response had 
been studied for more than 1 year(28). We selected 4  patients demonstrating the   12
presence of HLA-A2-restricted HBV-specific CD8+ T cells (Patient 1,2,3,4) and 2 
patients with no detectable HLA-A2 restricted HBV-specific CD8+ cells (Patient 5, 
6). The clinical, virological and histological data of the selected patients are shown in 
Table I.  Depletion of CD4+ CD25+ cells did not have any impact on HBeAg+ 
patients with consistently undetectable HBV-specific CD8+ cells for more than 1 year 
of analysis (Figure 3: Patients 5, 6), in whom such cells are likely to be deleted. In 
contrast, the frequency of HBV-specific CD8+ T cells was increased in PBMC 
depleted of CD4+CD25+ cells compared to total PBMC in all the other patients 
tested, irrespective of their HBeAg or viral replication status. Analysis of specific 
CD8+ expansion with HLA-tetramers (Tc18-27 and T-Melan-A) elicited results 
similar to those obtained by ICS (not shown). Importantly, when CD4+ CD25+ cells 
were added back to the culture, the expansion of HBV-specific CD8+ cells reduced to 
the levels observed before depletion (Figure 3c). Depletion of the CD4+ CD25+ 
population affected not only the expansion of HBV-specific CD8+ cells, but also their 
function. The proportion of tetramer+ CD8 cells able to produce interferon-gamma 
increased in cells expanded in the absence of CD4+ CD25+ cells (Figure 4).  
 
These results confirm the ability of circulating CD4+ CD25+ to suppress anti-viral 
immune response mediated by CD8+ T cells (10, 20). However this regulation is 
clearly non-antigen specific. In parallel with the expansion of HBV-specific CD8+ T 
cells, we performed control experiments using a Melan-A peptide, an HLA-A2 
restricted epitope able to induce CD8+ T cell responses in healthy control HLA-A2+ 
subjects (26). The impact of CD4-CD25+ depletion on the expansion of Melan-A 
specific CD8+ T cells was, in many patients, similar to that found in HBV-specific 
CD8+ cells (Figure 3b).    13
 
CD4+ CD25+ regulatory cells in patients with resolved HBV infection.  We analysed 
whether CD4+ CD25+ regulatory cells have an altered suppressive capacity in 
chronic compared to resolved patients. Differences in the functional suppression 
mediated by CD4+ CD25+ T cells have been shown in patients with multiple 
sclerosis versus healthy individuals(5). We therefore analysed whether circulating 
CD4+ CD25+ cells present in patients with resolved HBV infection can regulate 
CD8+ T cell expansion. The direct ex vivo frequency of CD4+ CD25+ cells in these 
patients was similar to that found in healthy subjects (R1=2.4 %; R2= 1.7%, R3= 
2.8%).  As shown in figure 5, depletion of CD4+ CD25+ cells further augmented the 
already robust HBV-specific CD8+ expansion present in resolved patients, showing 
that CD4+ CD25+ cells can also regulate CD8+ T cell responses in this setting.  
 
In conclusion, we have analysed the role of circulating CD4+ CD25+ cells in patients 
with different profiles of HBV infection. We could not find any marked elevation in 
circulating CD4+ CD25+ in ‘immunotolerant’ HBeAg+ patients, nor any temporal 
relationship between therapeutically induced disease activity and CD4+ CD25+ cell 
frequency, even though the pathogenesis of therapeutically induced hepatic flares is 
likely to differ from those occurring spontaneously.  
In addition, the data did not demonstrate a functional difference between the 
circulating CD4+CD25+ regulatory cells of chronic and resolved patients. Unlike 
murine HSV(24) and human HCV (23) infection, chronic HBV infection does not 
appear to be associated with a marked induction of this suppressor subset. However, 
this study was limited by  analysis of the circulating compartment only, and a detailed 
study of the frequency and function of intrahepatic CD4+CD25+ T cells might reveal   14
important differences between the heterogeneous populations of chronic patients. It 
cannot be excluded that antigen-specific regulatory cells (8) are preferentially induced 
in chronic HBV patients analogous to the presence of IL-10 producing HCV-specific 
CD4+(16) or CD8+ cells (2) in HCV infected patients. Studies have reported T cell 
production of IL-10 after stimulation with HBcAg (14).  
 
This study does however demonstrate that circulating CD4+ CD25+ cells are able to 
functionally suppress activation of CD8+ T cells specific for HBV and for unrelated 
antigens ex vivo. They are able to “fine tune” HBV-specific CD8 responses in the 
setting of both chronic and resolved infection. This ability to regulate the equilibrium 
between the impact of the infection and the host response could prevent an excessive 
pathogenetic response in chronic HBV, and could conversely inhibit complete viral 
clearance in patients who have resolved HBV, as has been shown in Leishmania 
infection (5).  The small increases in HBV-specific CD8 responses seen in patients 
with chronic HBV on depletion of the CD4+ CD25+ population could actually 
represent a useful increment to the critically low numbers found in this group of 
patients and may have practical implications for the clinical management of this 
subgroup. Future strategies could attempt to down-modulate the number or function 
of CD4+ CD25+ cells, in order to boost the frequency of HBV-specific CD8 
responses prior to therapeutic vaccination. 
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Figure 1.  Direct ex vivo frequency of circulating CD4+ CD25+ cells in HBV 
infected subjects. 1a) PBMC stained with anti-CD4 FITC and anti-CD25 PE. Cells 
were gated on live lymphocytes on the basis of their forward and side scatter 
properties. Fluorescent quadrants were set using anti-PE isotype matched control 
antibody. The frequencies of CD4+ CD25+ high cells were calculated using the 
quantity of cells included in the indicated (R2) gate. 1b) Direct ex vivo frequencies of 
CD4+CD25+ high cells out of total CD4 cells in hepatitis B chronic patients and 
healthy controls. The level of HBV-DNA ( copies/ml) and ALT (U/L) is indicated for 
each category. 1c) Ex vivo frequencies of CD4+CD25+ high was calculated in the 
indicated patients 2 weeks before, during and 2 weeks after an episode of 
therapeutically induced hepatic flare (ALT >100U/L and twice their initial baseline 




Figure 2. Temporal relationship  between CD4+ CD25+ frequency and HBV-
specific CD8+ T cell response.  Direct ex vivo frequencies of circulating CD4+ 
CD25+ cells were calculated at the indicated time points in the two HLA-A2+ 
patients indicated. In parallel, HBV-specific CD8+ T cell responses were calculated 
by stimulating PBMC with 10 HBV peptides representing known HLA-A2 restricted 
epitopes. The frequency of HBV-specific CD8+ cells was calculated with ICS after 8 
days of in vitro stimulation. Frequencies of IFN-gamma producing CD8+ cells are   21
only indicated for responding peptides. Patients were under Lamivudine therapy: 
HBV-DNA levels was < 10
5 copies/ml at all time points. 
 
Figure 3. Depletion of CD4+ CD25+ cells enhances the expansion of CD8+ T cells. 
All experiments were performed on short term lines derived from PBMC or CD4+ 
CD25+ depleted PBMC stimulated with HBV and Melan-A peptides. The frequency 
of peptide specific IFN-gamma producing CD8+ cells was tested with ICS after 8 
days of in vitro expansion. 3a) Dot plots show the frequency of env183-91 specific 
CD8 cells obtained in the different expansion conditions  (PBMC or CD4+ CD25+ 
depleted PBMC).  IFN-gamma producing CD8+ cells specific for env 183-91 were 
quantified with ICS by stimulating cells for 6 h with env 183-91 peptide (+pept). 
Negative controls are cells not stimulated with peptide (no pept). 3b) Panels indicate 
the frequencies of IFN-gamma producing  CD8+  T cells specific for HBV or Melan-
A peptides and obtained in the indicated patients. Note: the scale on the y-axis differs 
in the panels. 3c) CD4+CD25+ cells regulate CD8 expansion. Purified CD4+ CD25+ 
were added back into PBMC of Pt1 depleted of CD25+CD4+ cells 
(PBMC/CD4+CD25+ =20/1). Cells were stimulated with peptide core18-27. The 
frequency of core18-27 CD8 was analysed after 10 day of in vitro expansion. Bars 
indicate the frequency of expanded core18-27 CD8+ cells out of total CD8+ cells 
calculated by staining cells with Tc18-27 tetramers and anti-CD8. The experiment 
was repeated twice in Patient 1 with similar results. 
 
Figure 4. Depletion of CD4+CD25+ cells enhances anti-viral function of HBV-
specific CD8+ cells. Visualisation of IFN-gamma production of tetramer+ CD8 cells 
expanded in the presence or absence of CD4+CD25+. Dot plots represent live gated   22
CD8+ cells stained with Tc18-27 and anti IFN-gamma antibodies. Numbers indicate 
the proportion of Tetramer+ CD8+ cells producing IFN-gamma. Results were 
confirmed in 3 out of 3 different subjects tested.  
 
Figure 5. CD4+ CD25+ cells regulate the expansion of CD8+ T cells in patients 
with resolved HBV infection. PBMC and PBMC depleted of CD4+CD25+ cells 
from subjects who resolved HBV infection (n=3) were stimulated with HBV (core 18-
27) and Melan-A 26-35 peptides. After 8 days of in vitro expansion HBV-and Melan-
A specific CD8+ cells were visualised with tetramers (Tc18-27 and T Melan-A). 5a). 
Dot plots are representative of the results obtained in the 3 patients. Cells were gated 
on CD8+ live cells. 5b) Panels show the frequencies of core18-27 and Melan-A 26-35 
specific CD8 cells obtained in cells expanded from total PBMC and after depletion of 
CD4+CD25+ cells.   23

















Pt1 22  +  - +  2.4  x  10
4 36  ND 
P2 44  + _ +  1.0  x  10
6  57  Min NI    Min fibr. 
Pt3 43  +  + - 1.0  x  10
8  65  Mod NI  Mod fibr. 
Pt 4  36  +  +  -  4.0  x 10
8  55  Mod NI   Min fibr. 
Pt 5  25  +  +  -  5.3  x 10
8 70  Cirrhosis 
Pt 6  49  +  +  -  5.9  x 10
8  20  Min NI   Min fibr. 
Pt 7  25  +  +  -  5.8  x 10
8  66  Min NI    Min fibr. 
 
Legends: Min= minimal , Mod= moderate, Sev= severe, fibr.= fibrosis,  NI= 
necroinflammation 
ND.= not done 
 
 
 
 